D-Allulose Production: A Comprehensive Review and Update

The Enzyme Route to Allulose Is Maturing Fast

Allulose sits in a strange position. Formulators want it. Consumers respond to it. And production capacity is finally catching up. The driving force is enzymatic conversion. A new review in Foods (DOI: 10.3390/foods13162572) maps how far the technology has moved, from immobilized enzymes to engineered whole cells. If you specify or buy allulose, this paper is worth reading.

Background: The Regulatory Door Opened

The review starts from a simple fact. D-allulose only became commercially interesting after regulators cleared the path. In 2019, the FDA granted allulose GRAS status. China's NHC approved it as a new food ingredient. Those decisions did more than legalize an ingredient. They triggered serious investment in better production methods.

What the Study Did

The authors compiled the current landscape of D-allulose production. They focused on enzymatic conversion, covering four main technology tracks: enzyme immobilization, discovery of novel ketose 3-epimerases, directed evolution, and biosynthesis through metabolic pathway modification.

Each track attacks a different bottleneck. Immobilization keeps enzymes active and reusable. Novel enzyme discovery expands the range of catalysts. Directed evolution fine-tunes enzymes for industrial conditions. Metabolic pathway modification moves the whole process inside engineered cells.

Key Findings

One number stands out. A multi-enzyme cascade system converted D-fructose to D-allulose at a 75% conversion rate, with a total yield of 60%. The system worked directly on fruit juice bioconversion, converting the natural fructose already present in the juice.

That changes how you think about allulose sourcing. High conversion means less unreacted fructose left to separate. Fewer separation steps mean lower processing cost.

Technology track	What it targets	Reported result
Enzyme immobilization	Enzyme reuse across batches	Covered as a key production strategy
Novel enzyme discovery	New ketose 3-epimerases	Covered as a key production strategy
Directed evolution	Enzyme variants with better performance	Covered as a key production strategy
Metabolic pathway modification	Whole-cell biosynthesis	Covered as a key production strategy
Multi-enzyme cascade	Juice bioconversion of fructose	75% conversion, 60% total yield

What It Means for Manufacturers

The 75% conversion figure changes the cost conversation. Downstream purification is where allulose production gets expensive. Push conversion higher and you shrink that cost. The review suggests the enzymatic toolbox has matured enough to make that push.

The regulatory news matters just as much. FDA GRAS status and China's NHC approval open two major markets. If you are reformulating for those regions, the ingredient is available and accepted.

And the juice bioconversion angle deserves attention. If a beverage manufacturer can convert fructose in its own juice stream into allulose on-site, the ingredient purchase changes shape entirely. That is not a commercial product yet, but the review documents the science. The direction is clear.

When you talk to suppliers, ask pointed questions. What conversion rate does their process actually achieve? Are the enzymes immobilized or free? What is the real yield after purification? The gap between a lab cascade and a production line can be wide. The review gives you the vocabulary to ask better questions.

FAQ

Is allulose approved for food use? In the U.S., the FDA granted GRAS status in 2019. China's NHC has approved allulose as a new food ingredient. Regulatory status varies elsewhere, so check local rules before reformulating.

What makes the multi-enzyme cascade different? It combines multiple enzymes to push the conversion of D-fructose to D-allulose to 75%, with a total yield of 60%, demonstrated directly in fruit juice bioconversion.

Does the review cover enzyme discovery? Yes. Novel ketose 3-epimerase discovery and directed evolution are two of the four technology tracks examined, alongside immobilization and metabolic pathway modification.

The review makes a clear case. Enzymatic conversion has moved allulose production forward in a short time. A 75% conversion rate, regulatory approval in major markets, and a growing enzyme toolbox all point in the same direction. Allulose is no longer a specialty ingredient waiting for its moment. For buyers and formulators, the question is no longer whether to use it, but how quickly you can build it into your products.